Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobeline SCHEMBL8305826 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL290803 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL14029403 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL13900378 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL2905547 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL3308906 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL467021 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL8994428 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL4264391 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA | |
| Lobeline SCHEMBL467022 | 0.99 | CYP2D6 (0.97) | CYP2D6CYP1A2TSHRNFKB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2502 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544332-B2 | Lipid vesicle compositions with penetration enhancing agents | DDS RESEARCH INC. (CA) | 2026-02-10 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4608428-A2 | METHODS OF TREATMENT INVOLVING TOBACCO LEAF EXTRACTS TO HELP SMOKING CESSATION | NFL Biosciences (FR) | 2025-09-03 | — | — | EP | claimed |
| US-20250195505-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-06-19 | — | — | US | claimed |
| US-20250177309-A1 | ORAL PHARMACEUTICAL COMPOSITION WITH A PLANT ALKALOID FOR TREATMENT OF DEPENDENCIES | SOPHARMA AD (BG) | 2025-06-05 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250161296-A1 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | BIOBINA LLC | 2025-05-22 | — | — | US | claimed |
| US-12303503-B1 | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain | BIOBINA LLC (US) | 2025-05-20 | — | — | US | claimed |
| WO-2025037323-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DRY EYE DISEASE AND ASSOCIATED DISORDERS | KOTHAPUVARI PAVAN KUMAR (IN) | 2025-02-20 | — | — | WO | claimed |
| US-20240329053-A1 | A CELL-BASED METHOD FOR DETECTING POTENTIALLY PATHOGENIC AUTOANTIBODIES TO NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | TZARTOS NEURODIAGNOSTICS (GR) | 2024-10-03 | — | — | US | claimed |
| US-5536503-A | Controlled, sustained release delivery system for smoking cessation | DYNAGEN, INC. (US) | 1996-07-16 | — | — | US | claimed |
| EP-0720478-A1 | A CONTROLLED, SUSTAINED RELEASE DELIVERY SYSTEM FOR SMOKING CESSATION | DYNAGEN, INC. (US) | 1996-07-10 | — | — | EP | claimed |
| CN-1113270-A | Preparation for organic inclusion compound large crystal with second-order nonlinear optical effect | UNIV LIAONING NORMAL (CN) | 1995-12-13 | — | — | CN | claimed |
| WO-1995011678-A9 | USE OF NICOTINE SUBSTITUTES FOR THE TREATMENT OF NICOTINE WITHDRAWAL | — | 1995-06-08 | — | — | WO | claimed |
| US-5414005-A | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | DYNAGEN, INC. (US) | 1995-05-09 | — | — | US | claimed |
| WO-1995011678-A1 | USE OF NICOTINE SUBSTITUTES FOR THE TREATMENT OF NICOTINE WITHDRAWAL | DYNAGEN, INC. (US) | 1995-05-04 | — | — | WO | claimed |
| WO-1995011679-A1 | USE OF LOBELINE FOR THE TREATMENT OF NICOTINE WITHDRAWAL | DYNAGEN, INC. (US) | 1995-05-04 | — | — | WO | claimed |
| US-5403595-A | Controlled, sustained release delivery system for smoking cessation | DYNAGEN, INC. (US) | 1995-04-04 | — | — | US | claimed |
| WO-1992019241-A1 | A CONTROLLED, SUSTAINED RELEASE DELIVERY SYSTEM FOR SMOKING CESSATION | DYNAGEN, INC. (US) | 1992-11-12 | — | — | WO | claimed |
| US-4971079-A | CHEWING GUM FOR ADDICTION TO NICOTINE | TALAPIN VITALY I (SU) | 1990-11-20 | — | — | US | claimed |